淋巴内注射谷氨酸脱羧酶联合维生素D补充治疗新发1型糖尿病:双盲随机安慰剂对照IIb期试验
这项多中心双盲随机安慰剂对照IIb期试验纳入109例12-24岁新发1型糖尿病患者,评估淋巴内注射铝佐剂谷氨酸脱羧酶联合口服维生素D能否保护内源性胰岛素分泌。全分析集未达主要终点,但携带HLA DR3-DQ2的患者C肽保留显著优于安慰剂,提示精准医学分层治疗潜力。
要点
- 部分缓解(胰岛素剂量校正HbA1c≤9)显示阳性效应(P=0.0310),注射部位反应轻微短暂。
核心结论
- 淋巴内注射GAD-alum联合维生素D补充在新发1型糖尿病中总体未达主要终点。
- 携带HLA DR3-DQ2的患者接受治疗后C肽保留显著优于安慰剂,支持精准医学分层治疗。
研究设计与样本
- 多中心、随机、安慰剂对照、双盲IIb期试验,纳入109例12-24岁新发1型糖尿病患者。
- 患者糖尿病病程7-193天(88.8±51.4),血清GAD65自身抗体升高,空腹血清C肽>0.12 nmol/L。
- 随机接受三次淋巴内注射(间隔1个月)4 μg GAD-alum联合口服维生素D(每日2,000 IE,共120天)或安慰剂。
- 主要终点为基线至15个月混合餐耐量试验后刺激血清C肽平均AUC变化。
主要发现
- 部分缓解(胰岛素剂量校正HbA1c≤9)显示阳性效应(P=0.0310)。
- 注射部位反应轻微且短暂。
关键数值与推荐
- HLA DR3-DQ2定义为DRB1*03、DQB1*02:01。
- GAD-alum剂量为4 μg,淋巴内注射三次,间隔1个月。
- 维生素D补充为每日2,000 IE,共120天。
- 入组要求空腹血清C肽>0.12 nmol/L。
临床怎么用
- 对于携带HLA DR3-DQ2的新发1型糖尿病患者,淋巴内GAD-alum联合维生素D可能作为疾病修饰治疗选项。
- 治疗前应进行HLA DR3-DQ2基因分型以筛选潜在获益人群。
- 治疗总体耐受性良好,注射部位反应轻微短暂。
局限性
- 全分析集主要终点未达到,总体疗效有限。
- HLA DR3-DQ2亚组样本量较小(GAD-alum组n=29,安慰剂组n=17),需进一步验证。
- 随访时间为15个月,长期疗效未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of aluminum-formulated intralymphatic glutamic acid decarboxylase (GAD-alum) therapy combined with vitamin D supplementation in preserving endogenous insulin secretion in all patients with type 1 diabetes (T1D) or in a genetically prespecified subgroup. RESEARCH DESIGN AND METHODS: In a multicenter, randomized, placebo-controlled, double-blind trial, 109 patients aged 12-24 years (mean ± SD 16.4 ± 4.1) with a diabetes duration of 7-193 days (88.8 ± 51.4), elevated serum GAD65 autoantibodies, and a fasting serum C-peptide >0.12 nmol/L were recruited. Participants were randomized to receive either three intralymphatic injections (1 month apart) with 4 μg GAD-alum and oral vitamin D (2,000 IE daily for 120 days) or placebo. The primary outcome was the change in stimulated serum C-peptide (mean area under the curve [AUC] after a mixed-meal tolerance test) between baseline and 15 months. RESULTS: Primary end point was not met in the full analysis set (treatment effect ratio 1.091 [CI 0.845-1.408]; P = 0.5009). However, GAD-alum-treated patients carrying HLA DR3-DQ2 (n = 29; defined as DRB1*03, DQB1*02:01) showed greater preservation of C-peptide AUC (treatment effect ratio 1.557 [CI 1.126-2.153]; P = 0.0078) after 15 months compared with individuals receiving placebo with the same genotype (n = 17). Several secondary end points showed supporting trends, and a positive effect was seen in partial remission (insulin dose-adjusted HbA1c ≤9; P = 0.0310). Minor transient injection site reactions were reported. CONCLUSION: Intralymphatic administration of GAD-alum is a simple, well-tolerated treatment that together with vitamin D supplementation seems to preserve C-peptide in patients with recent-onset T1D carrying HLA DR3-DQ2. This constitutes a disease-modifying treatment for T1D with a precision medicine approach.
引用
- Ludvigsson J, Sumnik Z, Pelikanova T, et al. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial. Diabetes Care. 2021. PMID: 34021020. doi:10.2337/dc21-0318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。